Article

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

05/01/2026

Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 -Favorable safety and tolerability profiles observed – Full results to be presented in a late-breaking poster presentation at EASL 2026 -Topline Phase 3 data from AZURE-1 and AZURE-4 expected in H2 2026 Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS…

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

04/30/2026

Excerpt from the Press Release: BOSTON, April 27, 2026 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that it met the key secondary endpoint of PFS and showed additional compelling results in the randomized COMPANION-002 study, which evaluated tovecimig plus paclitaxel versus paclitaxel alone…

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development

04/29/2026

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Excerpt from the Press Release: PRINCETON, N.J. & TOKYO & ZURICH–(BUSINESS WIRE)–Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced…

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

04/24/2026

Excerpt from the Press Release: MUNICH & SAN FRANCISCO–(BUSINESS WIRE)–CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). The trial evaluates the company’s lead anti-GDF-15 antibody visugromab in combination with chemoimmunotherapy as a second-line (2L) treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC). The Phase 2b trial…

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

04/23/2026

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., April 6, 2026 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 dose escalation trial evaluating IDE574, a potential first-in-class oral small molecule equipotent dual inhibitor of the lysine…

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

04/22/2026

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the first interim analysis results of the Phase 2 B-SUPREME study of pevifoscorvir sodium…

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

04/20/2026

–JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline…

Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction

04/17/2026

U.S. pivotal trial to assess efficacy and safety of AURN001 compared to placebo Potential first-in-class cell therapy to regenerate corneal clarity and restore vision with a single procedure Excerpt from the Press Release: SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and…

Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer

04/14/2026

Excerpt from the Press Release: SAN DIEGO, April 7, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer…

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

04/10/2026

Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with…